Randomized phase II trial evaluating treatment with EGFR-TKI associated with antiestrogen in women with nonsquamous advanced-stage NSCLC: IFCT-1003 LADIE …
J Mazieres, F Barlesi, I Rouquette, O Molinier… - Clinical Cancer …, 2020 - AACR
… randomized, phase II study aimed to evaluate erlotinib plus fulvestrant versus erlotinib alone
… OS observed with erlotinib plus fulvestrant when considering all of the patients, a subgroup …
… OS observed with erlotinib plus fulvestrant when considering all of the patients, a subgroup …
XENERA-1: A randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients …
P Schmid, J Cortes, A Joaquim, NM Jañez… - Breast Cancer …, 2023 - Springer
… randomised Phase II study assessed xentuzumab plus everolimus and exemestane in
patients … plus fulvestrant versus fulvestrant; median PFS 1.9–2.7 months) [25, 26]. In both …
patients … plus fulvestrant versus fulvestrant; median PFS 1.9–2.7 months) [25, 26]. In both …
A phase II open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
DA Yardley, W Liggett, M Mainwaring, A Castrellon… - Clinical Breast …, 2020 - Elsevier
… In this phase II study, we used everolimus in addition to the most recent endocrine therapy
during which a patient's … therapies in this study: exemestane (11 patients; 23%), fulvestrant (10 …
during which a patient's … therapies in this study: exemestane (11 patients; 23%), fulvestrant (10 …
[HTML][HTML] Investigation of combination treatment with an aromatase inhibitor exemestane and carboplatin-based therapy for postmenopausal women with advanced …
PA Young, DC Márquez-Garbán, ZS Noor… - JTO clinical and …, 2021 - Elsevier
… patients with advanced NSCLC with high-dose fulvestrant in combination with erlotinib in a
phase 2 clinical trial … ) and overall survival (OS) in patients with wild-type EGFR tumors but not …
phase 2 clinical trial … ) and overall survival (OS) in patients with wild-type EGFR tumors but not …
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
… of this study, it is reasonable to use either fulvestrant or … In another randomized phase
II study (NCT01684215) of the … erlotinib in third-line therapy of KRAS-mutated metastatic …
II study (NCT01684215) of the … erlotinib in third-line therapy of KRAS-mutated metastatic …
[HTML][HTML] Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer
ZA Yochum, LP Stabile - Translational Lung Cancer Research, 2020 - ncbi.nlm.nih.gov
… phase II trial compared the combination of fulvestrant and erlotinib versus single-agent erlotinib
in NSCLC patients (… This work suggests that fulvestrant and dacomitinib may be effective …
in NSCLC patients (… This work suggests that fulvestrant and dacomitinib may be effective …
[HTML][HTML] Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic antitumor effects in NSCLC
AA Almotlak, M Farooqui, JM Siegfried - Journal of Thoracic Oncology, 2020 - Elsevier
… a phase II randomized clinical trial, the EGFR TKI erlotinib … patients who received the dual
therapy. The improvement when combining erlotinib (which only targets EGFR) with fulvestrant …
therapy. The improvement when combining erlotinib (which only targets EGFR) with fulvestrant …
Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
Y Yuan, JS Lee, SE Yost, T Stiller, MS Blanchard… - Journal of geriatric …, 2021 - Elsevier
… patients with ER + HER2 mutant MBC treated with neratinib plus fulvestrant, an overall RR of
18.2% (2… HER-directed TKI, specifically lapatinib and erlotinib, is reduced in the presence of …
18.2% (2… HER-directed TKI, specifically lapatinib and erlotinib, is reduced in the presence of …
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
A Patnaik, E Hamilton, Y Xing, DW Rasco, L Smith… - Cancers, 2022 - mdpi.com
… AIs or fulvestrant (as indicated), or other anticancer agents such as PI3K or mTOR inhibitors.
To this end, two ongoing phase II studies in China are evaluating FCN-437c alone versus in …
To this end, two ongoing phase II studies in China are evaluating FCN-437c alone versus in …
The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance
M Abdelmalak, R Singh, M Anwer, P Ivanchenko… - Cancers, 2022 - mdpi.com
… in the adjuvant setting of stage II/III h … study was a randomized, placebo-controlled phase
III study designed to assess the benefits of ribociclib in combination with fulvestrant for patients …
III study designed to assess the benefits of ribociclib in combination with fulvestrant for patients …